<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231026041021&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231026041021&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 26 Oct 2023 08:10:23 +0000</lastbuilddate>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Beta-Blockers in Stable Ischemic Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879789/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):e169. doi: 10.1016/j.jacc.2023.08.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879789/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879789</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.042>10.1016/j.jacc.2023.08.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879789</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Lucas C Godoy</dc:creator>
<dc:creator>Michael E Farkouh</dc:creator>
<dc:creator>Dennis T Ko</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Beta-Blockers in Stable Ischemic Heart Disease</dc:title>
<dc:identifier>pmid:37879789</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.042</dc:identifier>
</item>
<item>
<title>Beta-Blockers in Stable Ischemic Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):e167. doi: 10.1016/j.jacc.2023.07.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879788</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.034>10.1016/j.jacc.2023.07.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879788</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Elric Zweck</dc:creator>
<dc:creator>Shady Abohashem</dc:creator>
<dc:creator>Dhaval Kolte</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Beta-Blockers in Stable Ischemic Heart Disease</dc:title>
<dc:identifier>pmid:37879788</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.034</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1808. doi: 10.1016/j.jacc.2023.09.794.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879787</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.794>10.1016/j.jacc.2023.09.794</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879787</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:37879787</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.794</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1807. doi: 10.1016/j.jacc.2023.09.793.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879786</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.793>10.1016/j.jacc.2023.09.793</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879786</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:37879786</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.793</dc:identifier>
</item>
<item>
<title>Etiology of Early-Onset Complete Atrioventricular Block and Use of Implanted Cardiac Electronic Devices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1804-1806. doi: 10.1016/j.jacc.2023.08.040.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879785</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.040>10.1016/j.jacc.2023.08.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879785</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Gilad Margolis</dc:creator>
<dc:creator>Jennifer Chee</dc:creator>
<dc:creator>Mark Kazatsker</dc:creator>
<dc:creator>Ariel Roguin</dc:creator>
<dc:creator>Christopher Madias</dc:creator>
<dc:creator>Munther Homoud</dc:creator>
<dc:creator>Ofer Kobo</dc:creator>
<dc:creator>Nashed Hamuda</dc:creator>
<dc:creator>Eran Leshem</dc:creator>
<dc:creator>Guy Rozen</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Etiology of Early-Onset Complete Atrioventricular Block and Use of Implanted Cardiac Electronic Devices</dc:title>
<dc:identifier>pmid:37879785</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.040</dc:identifier>
</item>
<item>
<title>Cardiovascular Fellowship Training in Cardio-Obstetrics: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>The United States has the highest maternal mortality in the developed world with cardiovascular disease as the leading cause of pregnancy-related deaths. In response to this, the emerging subspecialty of cardio-obstetrics has been growing over the past decade. Cardiologists with training and expertise in caring for patients with cardiovascular disease in pregnancy are essential to provide effective, comprehensive, multidisciplinary, and high-quality care for this vulnerable population. This...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1792-1803. doi: 10.1016/j.jacc.2023.08.049.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The United States has the highest maternal mortality in the developed world with cardiovascular disease as the leading cause of pregnancy-related deaths. In response to this, the emerging subspecialty of cardio-obstetrics has been growing over the past decade. Cardiologists with training and expertise in caring for patients with cardiovascular disease in pregnancy are essential to provide effective, comprehensive, multidisciplinary, and high-quality care for this vulnerable population. This document provides a blueprint on incorporation of cardio-obstetrics training into cardiovascular disease fellowship programs to improve knowledge, skill, and expertise among cardiologists caring for these patients, with the goal of improving maternal and fetal outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879784</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.049>10.1016/j.jacc.2023.08.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879784</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Melinda B Davis</dc:creator>
<dc:creator>Natalie A Bello</dc:creator>
<dc:creator>Kathryn Berlacher</dc:creator>
<dc:creator>Colleen M Harrington</dc:creator>
<dc:creator>Jeannette P Lin</dc:creator>
<dc:creator>Kathryn J Lindley</dc:creator>
<dc:creator>Lindsay G Panah</dc:creator>
<dc:creator>Ki E Park</dc:creator>
<dc:creator>Candice K Silversides</dc:creator>
<dc:creator>Mary Norine Walsh</dc:creator>
<dc:creator>Gaby Weissman</dc:creator>
<dc:creator>Doreen DeFaria Yeh</dc:creator>
<dc:creator>Julie B Damp</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiovascular Fellowship Training in Cardio-Obstetrics: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37879784</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.049</dc:identifier>
</item>
<item>
<title>Resuscitation From Out-of-Hospital Cardiac Arrest: Location, Location, Location</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1789-1791. doi: 10.1016/j.jacc.2023.09.798.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879783</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.798>10.1016/j.jacc.2023.09.798</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879783</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Thomas D Rea</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Resuscitation From Out-of-Hospital Cardiac Arrest: Location, Location, Location</dc:title>
<dc:identifier>pmid:37879783</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.798</dc:identifier>
</item>
<item>
<title>Public Out-of-Hospital Cardiac Arrest in Residential Neighborhoods</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879782/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Two-thirds of public OHCAs occurred in residential neighborhoods with fewer resuscitative efforts before ambulance arrival and lower survival than in nonresidential areas. Targeted efforts to improve early CPR and defibrillation for public OHCA patients in residential neighborhoods are needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1777-1788. doi: 10.1016/j.jacc.2023.08.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although one-half of all public out-of-hospital cardiac arrests (OHCAs) occur outside private homes in residential neighborhoods, their characteristics and outcomes remain unexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors assessed interventions before ambulance arrival and survival for public OHCA patients in residential neighborhoods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Public OHCAs from Vienna (2018-2021) and Copenhagen (2016-2020) were designated residential neighborhoods or nonresidential areas. Interventions (cardiopulmonary resuscitation [CPR], automated external defibrillator [AED] attached, and defibrillation) and 30-day survival were compared using a generalized estimation equation model adjusted for age and time of day and presented as ORs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 1,052 and 654 public OHCAs from Vienna and Copenhagen, respectively, and 68% and 55% occurred in residential neighborhoods, respectively. The likelihood of CPR, defibrillation, and survival in residential neighborhoods vs nonresidential areas (reference) were as follows: CPR Vienna, 73% vs 78%, OR: 0.78 (95% CI: 0.57-1.06), CPR Copenhagen, 83% vs 90%, OR: 0.54 (95% CI: 0.34-0.88), and CPR combined, 76% vs 84%, OR: 0.70 (95% CI: 0.53-0.90); AED attached Vienna, 36% vs 44%, OR: 0.69 (95% CI: 0.53-0.90), AED attached Copenhagen, 21% vs 43%, OR: 0.33 (95% CI: 0.24-0.48), and AED attached combined, 31% vs 44%, OR: 0.53 (95% CI: 0.42-0.65); defibrillation Vienna, 14% vs 20%, OR: 0.61 (95% CI: 0.43-0.87), defibrillation Copenhagen, 16% vs 36%, OR: 0.35 (95% CI: 0.24-0.51), and defibrillation combined, 15% vs 27%, OR: 0.46 (95% CI: 0.36-0.61); and 30-day survival rate Vienna, 21% vs 26%, OR: 0.84 (95% CI: 0.58-1.20), 30-day survival rate Copenhagen, 33% vs 44%, OR: 0.65 (95% CI: 0.47-0.90), and 30-day survival rate combined, 25% vs 36%, OR: 0.73 (95% CI: 0.58-0.93).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Two-thirds of public OHCAs occurred in residential neighborhoods with fewer resuscitative efforts before ambulance arrival and lower survival than in nonresidential areas. Targeted efforts to improve early CPR and defibrillation for public OHCA patients in residential neighborhoods are needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879782/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879782</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.036>10.1016/j.jacc.2023.08.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879782</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Anne Juul Grabmayr</dc:creator>
<dc:creator>Fredrik Folke</dc:creator>
<dc:creator>Mads Christian Tofte Gregers</dc:creator>
<dc:creator>Louise Kollander</dc:creator>
<dc:creator>Nanna Bo</dc:creator>
<dc:creator>Linn Andelius</dc:creator>
<dc:creator>Theo Walter Jensen</dc:creator>
<dc:creator>Florian Ettl</dc:creator>
<dc:creator>Mario Krammel</dc:creator>
<dc:creator>Patrick Sulzgruber</dc:creator>
<dc:creator>Konstantin A Krychtiuk</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Annette Kjær Ersbøll</dc:creator>
<dc:creator>Carolina Malta Hansen</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Public Out-of-Hospital Cardiac Arrest in Residential Neighborhoods</dc:title>
<dc:identifier>pmid:37879782</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.036</dc:identifier>
</item>
<item>
<title>Initial Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion: Shifting Approaches to a Moving Target</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879781/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1774-1776. doi: 10.1016/j.jacc.2023.08.037.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879781/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879781</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.037>10.1016/j.jacc.2023.08.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879781</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonathan L Halperin</dc:creator>
<dc:creator>Kenneth J Rothman</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Initial Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion: Shifting Approaches to a Moving Target</dc:title>
<dc:identifier>pmid:37879781</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.037</dc:identifier>
</item>
<item>
<title>Family Screening in Gene-Elusive Hypertrophic Cardiomyopathy: Time for a Change or Should We Tread Cautiously?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879780/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1762-1764. doi: 10.1016/j.jacc.2023.09.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879780/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879780</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.003>10.1016/j.jacc.2023.09.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879780</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Juan Pablo Kaski</dc:creator>
<dc:creator>Gabrielle Norrish</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Family Screening in Gene-Elusive Hypertrophic Cardiomyopathy: Time for a Change or Should We Tread Cautiously?</dc:title>
<dc:identifier>pmid:37879780</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.003</dc:identifier>
</item>
<item>
<title>Patients With Hypertrophic Cardiomyopathy and Normal Genetic Investigations Have Few Affected Relatives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879779/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Systematic family screening of index patients with HCM and normal genetic investigations was associated with a low frequency of affected relatives who appeared to have a favorable prognosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1751-1761. doi: 10.1016/j.jacc.2023.08.041.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Current guidelines recommend that relatives of index patients with hypertrophic cardiomyopathy (HCM) are offered clinical investigations to identify individuals at risk of adverse disease complications and sudden cardiac death. However, the value of family screening in relatives of index patients with a normal genetic investigation of recognized HCM genes is largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to perform family screening among relatives of HCM index patients with a normal genetic investigation to establish the frequency of familial disease and the clinical characteristics of affected individuals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Clinical and genetic investigations were performed in consecutive and unrelated HCM index patients. Relatives of index patients who did not carry pathogenic/likely pathogenic variants in recognized HCM genes were invited for clinical investigations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 60% (270 of 453) of HCM index patients had a normal genetic investigation. A total of 80% of their relatives (751 of 938, median age 44 years) participated in the study. Of these, 5% (34 of 751) were diagnosed with HCM at baseline, whereas 0.3% (2 of 717 [751-34]) developed the condition during 5 years of follow-up. Their median age at diagnosis was 57 years (IQR: 51-70 years). Two-thirds (22 of 36) were diagnosed following family screening, whereas one-third (14 of 36) had been diagnosed previously because of cardiac symptoms, a murmur, or an abnormal electrocardiogram. None of the affected relatives experienced adverse disease complications. The risk of SCD was low.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Systematic family screening of index patients with HCM and normal genetic investigations was associated with a low frequency of affected relatives who appeared to have a favorable prognosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879779/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879779</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.041>10.1016/j.jacc.2023.08.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879779</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Søren K Nielsen</dc:creator>
<dc:creator>Frederikke G Hansen</dc:creator>
<dc:creator>Torsten B Rasmussen</dc:creator>
<dc:creator>Thomas Fischer</dc:creator>
<dc:creator>Jens F Lassen</dc:creator>
<dc:creator>Trine Madsen</dc:creator>
<dc:creator>Dorthe S Møller</dc:creator>
<dc:creator>Ib C Klausen</dc:creator>
<dc:creator>John B Brodersen</dc:creator>
<dc:creator>Morten S K Jensen</dc:creator>
<dc:creator>Jens Mogensen</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Patients With Hypertrophic Cardiomyopathy and Normal Genetic Investigations Have Few Affected Relatives</dc:title>
<dc:identifier>pmid:37879779</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.041</dc:identifier>
</item>
<item>
<title>Lipid Lowering After Myocardial Infarction: Too Little, Too Late</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 31;82(18):1748-1750. doi: 10.1016/j.jacc.2023.08.038.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879778</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.038>10.1016/j.jacc.2023.08.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879778</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:creator>Camille Granger</dc:creator>
<dc:creator>Niki Procopi</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lipid Lowering After Myocardial Infarction: Too Little, Too Late</dc:title>
<dc:identifier>pmid:37879778</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.038</dc:identifier>
</item>
<item>
<title>Time to Treat the Climate and Nature Crisis as One Indivisible Global Health Emergency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Oct 25. doi: 10.1001/jamacardio.2023.4488. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879620</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4488>10.1001/jamacardio.2023.4488</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879620</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Kamran Abbasi</dc:creator>
<dc:creator>Parveen Ali</dc:creator>
<dc:creator>Virginia Barbour</dc:creator>
<dc:creator>Thomas Benfield</dc:creator>
<dc:creator>Kirsten Bibbins-Domingo</dc:creator>
<dc:creator>Stephen Hancocks</dc:creator>
<dc:creator>Richard Horton</dc:creator>
<dc:creator>Laurie Laybourn-Langton</dc:creator>
<dc:creator>Robert Mash</dc:creator>
<dc:creator>Peush Sahni</dc:creator>
<dc:creator>Wadeia Mohammad Sharief</dc:creator>
<dc:creator>Paul Yonga</dc:creator>
<dc:creator>Chris Zielinski</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Time to Treat the Climate and Nature Crisis as One Indivisible Global Health Emergency</dc:title>
<dc:identifier>pmid:37879620</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4488</dc:identifier>
</item>
<item>
<title>Clopidogrel versus Aspirin Monotherapy Beyond 1 Year After PCI: STOPDAPT-2 5-Year Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879491/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Clopidogrel might be an attractive alternative to aspirin with a borderline ischemic benefit beyond 1-year after PCI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 18:S0735-1097(23)07750-1. doi: 10.1016/j.jacc.2023.10.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: It remains unclear whether clopidogrel is better suited than aspirin as the long-term antiplatelet monotherapy following dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We compared clopidogrel monotherapy following 1-month DAPT (clopidogrel group) with aspirin monotherapy following 12-month DAPT (aspirin group) after PCI for 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: STOPDAPT-2 is a multicenter, open-label, adjudicator-blinded, randomized clinical trial conducted in Japan. Patients who underwent PCI with cobalt-chromium everolimus-eluting stents were randomized in a 1-to-1 fashion either to clopidogrel or aspirin groups. The primary endpoint was a composite of cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, or definite stent thrombosis) or major bleeding (TIMI major or minor bleeding).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 3005 study patients (Age: 68.6±10.7 years; Women: 22.3%; Acute coronary syndrome: 38.3%), 2934 patients (97.6%) completed 5-year follow-up (adherence to the study drugs at 395 days: 84.7% and 75.9%). Clopidogrel group compared with aspirin group was noninferior, but not superior for the primary endpoint (11.75% and 13.57%; HR 0.85 [95%CI: 0.70-1.05], P<sub>noninferiority</sub>&lt;0.001, P<sub>superiority</sub>=0.13), while it was superior for the cardiovascular outcomes (8.61% and 11.05%, HR 0.77 [95%CI: 0.61-0.97], P=0.03), and not superior for major bleeding (4.44% and 4.92%; HR 0.89 [95%CI: 0.64-1.25], P=0.51). By the 1-year landmark analysis, clopidogrel was numerically, but not significantly, superior to aspirin for cardiovascular events (6.79% and 8.68%; HR 0.77 [95%CI: 0.59-1.01], P=0.06) without difference in major bleeding (3.99% and 3.32%; HR 1.23 [95%CI: 0.84-1.81], P=0.31).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Clopidogrel might be an attractive alternative to aspirin with a borderline ischemic benefit beyond 1-year after PCI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879491/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879491</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.013>10.1016/j.jacc.2023.10.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879491</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Hirotoshi Watanabe</dc:creator>
<dc:creator>Takeshi Morimoto</dc:creator>
<dc:creator>Masahiro Natsuaki</dc:creator>
<dc:creator>Ko Yamamoto</dc:creator>
<dc:creator>Yuki Obayashi</dc:creator>
<dc:creator>Ryusuke Nishikawa</dc:creator>
<dc:creator>Kenji Ando</dc:creator>
<dc:creator>Koh Ono</dc:creator>
<dc:creator>Kazushige Kadota</dc:creator>
<dc:creator>Satoru Suwa</dc:creator>
<dc:creator>Itsuro Morishima</dc:creator>
<dc:creator>Ruka Yoshida</dc:creator>
<dc:creator>Yoshiki Hata</dc:creator>
<dc:creator>Masaharu Akao</dc:creator>
<dc:creator>Masahiro Yagi</dc:creator>
<dc:creator>Nobuhiro Suematsu</dc:creator>
<dc:creator>Yoshihiro Morino</dc:creator>
<dc:creator>Takafumi Yokomatsu</dc:creator>
<dc:creator>Itaru Takamisawa</dc:creator>
<dc:creator>Toshiyuki Noda</dc:creator>
<dc:creator>Masayuki Doi</dc:creator>
<dc:creator>Hideki Okayama</dc:creator>
<dc:creator>Yuichi Nakamura</dc:creator>
<dc:creator>Kiyoshi Hibi</dc:creator>
<dc:creator>Hiroki Sakamoto</dc:creator>
<dc:creator>Teruo Noguchi</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>STOPDAPT-2 investigators</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clopidogrel versus Aspirin Monotherapy Beyond 1 Year After PCI: STOPDAPT-2 5-Year Results</dc:title>
<dc:identifier>pmid:37879491</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.013</dc:identifier>
</item>
<item>
<title>Guiding Intervention for Complex Coronary Lesions by Optical Coherence Tomography or Intravascular Ultrasound</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879490/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Among patients with complex coronary-artery lesions, OCT-guided PCI showed a similar risk of primary-composite event of death from cardiac causes, target-vessel-related myocardial infarction, or target-vessel revascularization as compared with IVUS-guided PCI.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 17:S0735-1097(23)07816-6. doi: 10.1016/j.jacc.2023.10.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Optical coherence tomography (OCT) and intravascular ultrasound (IVUS) have shown comparable outcomes in guiding percutaneous coronary intervention (PCI). However, their comparative effectiveness in complex coronary-artery lesions remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study compared the effectiveness and safety of OCT-guided vs. IVUS-guided PCI for complex coronary-artery lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a pre-specified, main subgroup analysis of complex coronary-artery lesions in the OCTIVUS trial, which included unprotected left main disease, bifurcation disease, an aorto-ostial lesion, a chronic total occlusion, a severely calcified lesion, an in-stent restenotic lesion, a diffuse long lesion, or multivessel PCI. The primary end-point was a composite of death from cardiac causes, target-vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In 2008 randomized patients, 1475 (73.5%) underwent imaging-guided PCI for complex coronary-artery lesions; 719 (48.7%) received OCT-guided and 756 (51.3%) received IVUS-guided PCI. At a median follow-up of 2.0 years, primary end-point event had occurred in 47 (6.5%) patients in the OCT-guided group and in 56 (7.4%) patients in the IVUS-guided group (hazard ratio [HR] 0.87; 95% confidence interval [CI] 0.59-1.29; P=0.50). These findings were consistent in adjusted analyses. The incidence of contrast-induced nephropathy was similar between two groups (1.9% vs. 1.5%; P=0.46). The incidence of major procedural complications was lower in the OCT-guided group than the IVUS-guided group (1.7% vs. 3.4%; P=0.03).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with complex coronary-artery lesions, OCT-guided PCI showed a similar risk of primary-composite event of death from cardiac causes, target-vessel-related myocardial infarction, or target-vessel revascularization as compared with IVUS-guided PCI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879490/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879490</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.017>10.1016/j.jacc.2023.10.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879490</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Do-Yoon Kang</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>Sung-Cheol Yun</dc:creator>
<dc:creator>Seung-Ho Hur</dc:creator>
<dc:creator>Yun-Kyeong Cho</dc:creator>
<dc:creator>Cheol Hyun Lee</dc:creator>
<dc:creator>Soon Jun Hong</dc:creator>
<dc:creator>Subin Lim</dc:creator>
<dc:creator>Sang-Wook Kim</dc:creator>
<dc:creator>Hoyoun Won</dc:creator>
<dc:creator>Jun-Hyok Oh</dc:creator>
<dc:creator>Jeong Cheon Choe</dc:creator>
<dc:creator>Young Joon Hong</dc:creator>
<dc:creator>Yong-Hoon Yoon</dc:creator>
<dc:creator>Hoyun Kim</dc:creator>
<dc:creator>Yeonwoo Choi</dc:creator>
<dc:creator>Jinho Lee</dc:creator>
<dc:creator>Young Won Yoon</dc:creator>
<dc:creator>Soo-Joong Kim</dc:creator>
<dc:creator>Jang-Ho Bae</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:creator>OCTIVUS Investigators*</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Guiding Intervention for Complex Coronary Lesions by Optical Coherence Tomography or Intravascular Ultrasound</dc:title>
<dc:identifier>pmid:37879490</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.017</dc:identifier>
</item>
<item>
<title>Cardiac Re-operation or Transcatheter Mitral Valve Replacement for Patients with Failed Mitral Prostheses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879489/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In this large cohort of Medicare beneficiaries with failed mitral prostheses, outcomes were similar between redo SMVR and TMVR at 3 years, with TMVR showing lower initial risk but a higher risk of MACE after 6 months. These findings highlight the importance of striking a balance between surgical risk, anticipated longevity, and hospital expertise when selecting interventions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 16:S0735-1097(23)07753-7. doi: 10.1016/j.jacc.2023.10.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Evidence is limited regarding patient outcomes comparing redo surgical mitral valve replacement (redo SMVR) versus transcatheter mitral valve replacement (TMVR) for failed prostheses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To compare the outcomes of redo SMVR versus TMVR in patients with failed prostheses, as well as evaluate the association between case volume and outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Medicare beneficiaries aged ≥65 years who underwent redo SMVR or TMVR for failed mitral prostheses between 2016 and 2020 were included. Primary endpoint was mid-term (up to 3 years) major adverse cardiovascular events (MACE), including all-cause death, heart failure rehospitalization, stroke, or reintervention. Propensity score-matched analysis was used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 4,293 patients were included (redo SMVR:64%;TMVR:36%). TMVR recipients were older with higher comorbidity burden. In matched cohort (n=1,317 in each group), mid-term risk of MACE was similar (adjusted HR, 0.92; 95%CI, 0.80-1.04; p=0.2). However, landmark analysis revealed a lower risk of MACE with TMVR in the first 6 months (adjusted HR, 0.75; 95%CI, 0.63-0.88; p&lt;0.001) albeit a higher risk beyond 6 months (adjusted HR, 1.28; 95%CI, 1.04-1.58; p=0.02). Increasing procedural volume was associated with decreased risk of mid-term MACE after redo SMVR (p=0.001), but not after TMVR (p=0.3).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this large cohort of Medicare beneficiaries with failed mitral prostheses, outcomes were similar between redo SMVR and TMVR at 3 years, with TMVR showing lower initial risk but a higher risk of MACE after 6 months. These findings highlight the importance of striking a balance between surgical risk, anticipated longevity, and hospital expertise when selecting interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879489/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879489</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.014>10.1016/j.jacc.2023.10.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879489</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Hiroki A Ueyama</dc:creator>
<dc:creator>Yoshihisa Miyamoto</dc:creator>
<dc:creator>Atsuyuki Watanabe</dc:creator>
<dc:creator>Hiroshi Gotanda</dc:creator>
<dc:creator>Stamatios Lerakis</dc:creator>
<dc:creator>Azeem Latib</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Toshiki Kuno</dc:creator>
<dc:creator>Yusuke Tsugawa</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Re-operation or Transcatheter Mitral Valve Replacement for Patients with Failed Mitral Prostheses</dc:title>
<dc:identifier>pmid:37879489</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.014</dc:identifier>
</item>
<item>
<title>Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37880496/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>Aortic blood flow patterns are closely linked to the morphology and function of the left ventricle, aortic valve and aorta. These flow patterns demonstrate the exceptional adaptability of the cardiovascular system to maintain blood circulation under a broad range of haemodynamic workloads and can be altered in various pathophysiological states. For instance, normal ascending aortic systolic flow is predominantly laminar, whereas abnormal aortic systolic flow is associated with increased...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 25. doi: 10.1038/s41569-023-00943-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Aortic blood flow patterns are closely linked to the morphology and function of the left ventricle, aortic valve and aorta. These flow patterns demonstrate the exceptional adaptability of the cardiovascular system to maintain blood circulation under a broad range of haemodynamic workloads and can be altered in various pathophysiological states. For instance, normal ascending aortic systolic flow is predominantly laminar, whereas abnormal aortic systolic flow is associated with increased eccentricity, vorticity and flow reversal. These flow abnormalities result in reduced aortic conduit function and increased energy loss in the cardiovascular system. Emerging evidence details the association of these flow patterns with loss of aortic compliance, which leads to adverse left ventricular remodelling, poor tissue perfusion, and an increased risk of morbidity and death. In this Perspective article, we review the evidence for the link between aortic flow-related abnormalities and cardiovascular disease and how these changes in aortic flow patterns are emerging as a therapeutic target for aortic valve intervention in first-in-human studies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37880496/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37880496</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00943-6>10.1038/s41569-023-00943-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37880496</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Pankaj Garg</dc:creator>
<dc:creator>Michael Markl</dc:creator>
<dc:creator>Janarthanan Sathananthan</dc:creator>
<dc:creator>Stephanie L Sellers</dc:creator>
<dc:creator>Chris Meduri</dc:creator>
<dc:creator>João Cavalcante</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention</dc:title>
<dc:identifier>pmid:37880496</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00943-6</dc:identifier>
</item>
<item>
<title>Clinical implementation of partial oral treatment in infective endocarditis: the Danish POETry study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: After clinical implementation of the POET regimen almost half of the possible candidates with IE received oral step-down antibiotic therapy. Patients in the IV group had more serious risk factors for negative outcomes. At 6-month follow-up, there was a numerically but not statistically significant difference towards a lower incidence of the primary outcome, a lower incidence of all-cause mortality and a reduced length of stay in the PO group. Due to the observational design of the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 25:ehad715. doi: 10.1093/eurheartj/ehad715. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In the Partial Oral Treatment of Endocarditis (POET) trial, stabilized patients with left-sided infective endocarditis (IE) were randomized to oral step-down antibiotic therapy (PO) or conventional continued intravenous antibiotic treatment (IV), showing non-inferiority after 6 months. In this study, the first guideline-driven clinical implementation of the oral step-down POET regimen was examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with IE, caused by Staphylococcus aureus, Enterococcus faecalis, Streptococcus spp. or coagulase-negative staphylococci diagnosed between May 2019 and December 2020 were possible candidates for initiation of oral step-down antibiotic therapy, at the discretion of the treating physician. The composite primary outcome in patients finalizing antibiotic treatment consisted of embolic events, unplanned cardiac surgery, relapse of bacteraemia and all-cause mortality within 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 562 patients [median age 74 years (IQR, interquartile range, 65-80), 70% males] with IE were possible candidates; PO was given to 240 (43%) patients and IV to 322 (57%) patients. More patients in the IV group had IE caused by S. aureus, or had an intra-cardiac abscess, or a pacemaker and more were surgically treated. The primary outcome occurred in 30 (13%) patients in the PO group and in 59 (18%) patients in the IV group (P = .051); in the PO group, 20 (8%) patients died vs. 46 (14%) patients in the IV group (P = .024). PO-treated patients had a shorter median length of stay [PO 24 days (IQR 17-36) vs. IV 43 days (IQR 32-51), P &lt; .001].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: After clinical implementation of the POET regimen almost half of the possible candidates with IE received oral step-down antibiotic therapy. Patients in the IV group had more serious risk factors for negative outcomes. At 6-month follow-up, there was a numerically but not statistically significant difference towards a lower incidence of the primary outcome, a lower incidence of all-cause mortality and a reduced length of stay in the PO group. Due to the observational design of the study, the lower mortality may to some extent reflect selection bias and unmeasured confounding. Clinical implementation of PO regimens seemed feasible and safe.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879115</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad715>10.1093/eurheartj/ehad715</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879115</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Mia Marie Pries-Heje</dc:creator>
<dc:creator>Julie Glud Hjulmand</dc:creator>
<dc:creator>Ingrid Try Lenz</dc:creator>
<dc:creator>Rasmus Bo Hasselbalch</dc:creator>
<dc:creator>Jonas Agerlund Povlsen</dc:creator>
<dc:creator>Nikolaj Ihlemann</dc:creator>
<dc:creator>Nana Køber</dc:creator>
<dc:creator>Marlene Lyngborg Tofterup</dc:creator>
<dc:creator>Lauge Østergaard</dc:creator>
<dc:creator>Morten Dalsgaard</dc:creator>
<dc:creator>Daniel Faurholt-Jepsen</dc:creator>
<dc:creator>Malene Wienberg</dc:creator>
<dc:creator>Ulrik Christiansen</dc:creator>
<dc:creator>Niels Eske Bruun</dc:creator>
<dc:creator>Emil Fosbøl</dc:creator>
<dc:creator>Claus Moser</dc:creator>
<dc:creator>Kasper Karmark Iversen</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clinical implementation of partial oral treatment in infective endocarditis: the Danish POETry study</dc:title>
<dc:identifier>pmid:37879115</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad715</dc:identifier>
</item>
<item>
<title>One of the open ductus dissected during pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879111/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 25:ehad687. doi: 10.1093/eurheartj/ehad687. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879111/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879111</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad687>10.1093/eurheartj/ehad687</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879111</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Anne J Koppelaar</dc:creator>
<dc:creator>Alex J Eggink</dc:creator>
<dc:creator>Johannes M I H Gho</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>One of the open ductus dissected during pregnancy</dc:title>
<dc:identifier>pmid:37879111</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad687</dc:identifier>
</item>
<item>
<title>Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37879100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 25:ehad674. doi: 10.1093/eurheartj/ehad674. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37879100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37879100</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad674>10.1093/eurheartj/ehad674</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37879100</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction</dc:title>
<dc:identifier>pmid:37879100</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad674</dc:identifier>
</item>
<item>
<title>Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37878786/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231026041021&amp;v=2.17.9.post6+86293ac
      <description>Background: Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (ACS). The aim of this study was to investigate whether ticagrelor monotherapy after &lt;1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with ACS. Methods: In this randomized, open-label,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 25. doi: 10.1161/CIRCULATIONAHA.123.066943. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (ACS). The aim of this study was to investigate whether ticagrelor monotherapy after &lt;1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with ACS. <b>Methods:</b> In this randomized, open-label, non-inferiority trial, 2850 patients with ACS who underwent DES implantation at 24 centres in South Korea were randomly assigned (1:1) to receive either ticagrelor monotherapy (90 mg twice daily) after &lt;1 month of DAPT (n=1426) or 12 months of ticagrelor-based DAPT (n=1424) between Apr 24, 2019, and May 31, 2022. The primary endpoint was the net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure in the intention-to-treat population. Key secondary endpoints were the individual components of the primary endpoint. <b>Results:</b> Among 2850 patients who were randomized (mean age, 61 years; 40% ST-elevation myocardial infarction), 2823 (99.0%) completed the trial. Aspirin was discontinued at a median of 16 days (interquartile range, 12 to 25 days) in the group receiving ticagrelor monotherapy after &lt;1 month of DAPT. The primary endpoint occurred in 40 patients (2.8%) in the group receiving ticagrelor monotherapy after &lt;1-month DAPT, and in 73 patients (5.2%) in the ticagrelor-based 12-month DAPT group (hazard ratio [HR], 0.54 [95% CI, 0.37-0.80]; <i>P</i>&lt;0.001 for noninferiority; <i>P</i>=0.002 for superiority). This finding was consistent in the per-protocol population as a sensitivity analysis. The occurrence of major bleeding was significantly lower in the ticagrelor monotherapy after &lt;1-month DAPT group compared with the 12-month DAPT group (1.2% versus 3.4%; HR, 0.35 [95% CI, 0.20-0.61]; <i>P</i>&lt;0.001). <b>Conclusions:</b> This study provides evidence that stopping aspirin within 1 month for ticagrelor monotherapy is both noninferior and superior to 12-month DAPT as for the 1-year composite outcome of death, myocardial infarction, stent thrombosis, stroke, and major bleeding, primarily due to a significant reduction in major bleeding, among ACS patients receiving DES implantation. Low event rates which may suggest enrolment of relatively non-high-risk patients should be considered in interpreting the trial.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37878786/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231026041021&v=2.17.9.post6+86293ac">37878786</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066943>10.1161/CIRCULATIONAHA.123.066943</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37878786</guid>
<pubDate>Wed, 25 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Sung-Jin Hong</dc:creator>
<dc:creator>Seung-Jun Lee</dc:creator>
<dc:creator>Yongsung Suh</dc:creator>
<dc:creator>Kyeong Ho Yun</dc:creator>
<dc:creator>Tae Soo Kang</dc:creator>
<dc:creator>Sanghoon Shin</dc:creator>
<dc:creator>Sung Woo Kwon</dc:creator>
<dc:creator>Jun-Won Lee</dc:creator>
<dc:creator>Deok-Kyu Cho</dc:creator>
<dc:creator>Jong-Kwan Park</dc:creator>
<dc:creator>Jang-Whan Bae</dc:creator>
<dc:creator>Woong Cheol Kang</dc:creator>
<dc:creator>Seunghwan Kim</dc:creator>
<dc:creator>Yong-Joon Lee</dc:creator>
<dc:creator>Chul-Min Ahn</dc:creator>
<dc:creator>Jung-Sun Kim</dc:creator>
<dc:creator>Byeong-Keuk Kim</dc:creator>
<dc:creator>Young-Guk Ko</dc:creator>
<dc:creator>Donghoon Choi</dc:creator>
<dc:creator>Yangsoo Jang</dc:creator>
<dc:creator>Myeong-Ki Hong</dc:creator>
<dc:creator>T-PASS investigators</dc:creator>
<dc:date>2023-10-25</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial</dc:title>
<dc:identifier>pmid:37878786</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066943</dc:identifier>
</item>





























</channel>
</rss>